Evidence map›Paper›PMID 32973054›Full record

ArticleBMJ open2020

World Café approach: exploring the future vision of oral anticoagulants for patients with atrial fibrillation (AF) in Ireland.

Aileen Murphy, Stephen Brosnan, Stephen McCarthy, Paidi O'Raghallaigh, Colin Bradley, Ann Kirby

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Aileen MurphyDepartment of Economics, Cork University Business School, University College Cork, Cork, Ireland aileen.murphy@ucc.ie.ORCID 0000-0003-3062-0692
Stephen BrosnanDepartment of Economics, Cork University Business School, University College Cork, Cork, Ireland.
Stephen McCarthyDepartment of Business Information Systems, Cork University Business School, University College Cork, Cork, Ireland.
Paidi O'RaghallaighINFANT Research Centre, University College Cork, Cork, Ireland.
Colin BradleyDepartment of General Practice, University College Cork, Cork, Ireland.
Ann KirbyDepartment of Economics, Cork University Business School, University College Cork, Cork, Ireland.ORCID 0000-0002-9043-5483
University College Cork · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo explore and reflect on the current anticoagulation therapy offered to patients with atrial fibrillation (AF), potential challenges and the future vision for oral anticoagulants for patients with AF and healthcare professionals in Ireland.

designA multistakeholder focus group using a World Café approach.

participantsNine participants from academic, clinical and health backgrounds attended the focus group together with a facilitator.

resultsEnhanced patient empowerment; more effective use of technology and developing system-based medical care pathways would provide improved supports for AF management. The challenges in providing these include cost and access issues, the doctor-patient relationship and the provision of education. While consensus for developing evidence-based pathways to maximise efficiency and effectiveness of AF treatment was evident, it would require a shared vision between stakeholders of integrated care. The benefits of embracing technological advances for clinicians and patients were evident; however, clinicians indicate this can increase pressure on already stretched resources; coupled with institutional barriers (including scarce resources) arising from the complex nature of anticoagulation for patients with AF, which emerged strongly. Including the unpredictable nature of warfarin, hidden costs associated with monitoring, adverse clinical effects, different patient cohorts (including those prescribed anticoagulant for the first time vs those switching from warfarin to a new oral anticoagulant (NOAC)), non-adherence concerns and undesirable impacts on patients' daily lives.

conclusionsWhile anticoagulation therapy for patients with AF using NOACs has been widely adopted and is diffusing into routine practice, significant operationalisation issues and barriers to effective treatment/management persist. The reflections reported in this study are a catalyst for future discussion and research.

Indexed as

Atrial FibrillationStrokeAdministration, OralAnticoagulantsHumansIrelandPhysician-Patient RelationsAnticoagulantsadult cardiologyprotocols & guidelinesqualitative researchstroke medicine

Identifiers

PMID32973054
PMCPMC7517561
OpenAlexW3087948194

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.